Get access

Tumor-initiating cells and tumor vascularization

Authors

  • Li-Zhi Zhang MD,

    1. Department of Orthopedic Surgery, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China
    Search for more papers by this author
  • Chang-Qing Zhang MD,

    1. Department of Orthopedic Surgery, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China
    Search for more papers by this author
  • Zhen-Yu Yan MD,

    1. Department of Hematology, Affiliated Hospital of North China Coal Medical College, Tangshan, Hebei Province, China
    Search for more papers by this author
  • Qing-Cheng Yang MD,

    1. Department of Orthopedic Surgery, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China
    Search for more papers by this author
  • Yao Jiang MD,

    Corresponding author
    1. Department of Orthopedic Surgery, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China
    • Department of Orthopedic Surgery, Shanghai Sixth People's Hospital, Medical College, Shanghai Jiaotong University, No.600 Yishan Road, Shanghai 200233 China.
    Search for more papers by this author
  • Bing-Fang Zeng MD

    1. Department of Orthopedic Surgery, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China
    Search for more papers by this author

  • Conflict of interest: The authors have no conflicts of interest to disclose.

Abstract

Tumor-initiating cells (TICs) with stem-like cell properties initiate and sustain progressive growth, resulting in a heterogeneous tumor mass. The survival and growth of tumors rely on the development of a vasculature to provide nutrients and oxygen. Crosstalk between TICs and vascularization may be one of the central players in the initiation, long-term maintenance, and progression of tumors. This review surveys current evidence concerning the crosstalk that occurs in tumor/stromal interactions, including genetic change, vascular niche, hypoxia, and dormancy of tumors. A better understanding of this crosstalk might help provide the basis for developing more effective therapeutic drug targets. Pediatr Blood Cancer 2011;56:335–340. © 2010 Wiley-Liss, Inc.

Ancillary